DURECT (DRRX)
(Real Time Quote from BATS)
$1.18 USD
-0.06 (-4.84%)
Updated Sep 25, 2024 12:02 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Brokerage Reports
DURECT Corporation [DRRX]
Reports for Purchase
Showing records 1 - 20 ( 144 total )
Company: DURECT Corporation
Industry: Medical - Drugs
2Q Recap: Awaiting FDA Meeting Minutes to Confirm Phase 3 Trial Design; Cash Runway to YE24; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Larsucosterol Granted BTD for AH; Phase 3 Pivotal Trial Design Announcement As Next Major Milestone; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
1Q Recap: FDA Type C Meeting Confirmed Single Pivotal Study to Support Larsucosterol''s Approval in AH
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
4Q Recap; We Expect Clarity on Larsucosterol''s Path Forward in AH in 2Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Charles River to Help Market ALZET; EOP2 Meeting in 1Q24 to Determine Larsucosterol''s Path Forward; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
3Q Recap: We Look For EOP2 Meeting With The FDA in 1Q24 to Determine Larsucosterol''s Future; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Phase 2b AHFIRM in Severe AH Is a Flop, Missing Primary and Secondary Endpoints; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Last Patient''s Last Visit Completed in AHFIRM Phase 2b AH Trial; 4Q23 Top-Line Data In-Line With Guidance; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
2Q Recap: With LPLV in Early September, We Await AHFIRM Topline Data in 4Q23; Affirm Buy, Trim PT to $27
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Countdown to Potentially Transformational Catalyst: Phase 2b AHFIRM Study Completes Enrollment; Top-line Data in 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
1Q Recap: AHFIRM on the Cusp of Full Enrollment; Potential Registrational Data Readout in 2H23; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Study Cross Comparisons Highlight Larsucosterol''s Efficacy in AH Over SoC
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
4Q Recap; AHFIRM Complete Enrollment Expected 2Q23; Positive Data Could Lead to $3B+ Opportunity; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
1-for-10 Reverse Stock Split Becomes Effective; Adjusting PT to $35 on Model Updates; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
3Q Recap; AHFIRM Pace of Enrollment Faster Than Expected; Complete Enrollment Now Expected in 2Q23; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Innocoll Launches POSIMIR in the U.S., Triggering $2M Milestone Payment to DURECT; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
2Q Recap; We Expect AHFIRM''s Modified Endpoint to Reflect Larsucosterol''s Expanded Benefit in AH; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
1Q Recap; AHFIRM Pace of Enrollment Begins to Accelerate; Last Patient Dosing Expected in Mid-2023; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
With AHFIRM''s Complete Enrollment Expected in Mid-2023, DURECT Works to Expand Awareness For AH
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
4Q Recap; DURECT Expects New AHFIRM Sites to Support Complete Enrollment in Mid-2023; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E